Mumbai, January 13, 2026
Metropolis Healthcare Limited (NSE: METROPOLIS | BSE: 542650) on Tuesday announced the launch of its Centre of Genomics, strengthening its capabilities in advanced genomics, molecular diagnostics, precision medicine, and genomic research, as the company sharpens its focus on high-impact, data-driven diagnostics.
The newly launched Centre of Genomics brings together Metropolis’ existing genomics strengths under a unified national framework aimed at delivering clinically actionable genomic insights across the care continuum. The initiative targets key clinical specialties, including oncology, reproductive health, neurology, transplant immunology, and rare diseases, positioning genomics as a core growth engine for the diagnostics major.
Advanced Sequencing Infrastructure Scales Research Capability
As part of the Centre’s technology backbone, Metropolis has augmented its sequencing infrastructure with the deployment of Illumina’s NovaSeq X Series for research purposes. The NovaSeq X Plus system offers significantly higher throughput, speed, and accuracy compared with earlier platforms, with the capacity to generate more than 20,000 whole genomes annually.The enhanced sequencing capability is expected to accelerate genomic research, improve turnaround times, and broaden access to advanced genomic insights, supporting both clinical diagnostics and research-led initiatives.
National Genomics Network Anchored in Mumbai and Delhi NCR
The Centre of Genomics is backed by two national referral genomics laboratories located in Mumbai and Delhi NCR. These facilities integrate Metropolis’ Global Reference Laboratory in Mumbai with the specialised genomics laboratory added through the Core Diagnostics acquisition in the Delhi NCR region.Together, the combined infrastructure supports a wide portfolio of next-generation sequencing-based assays, supported by robust bioinformatics, advanced interpretation frameworks, and multidisciplinary clinical expertise. The integrated model is designed to translate complex genomic data into clear, reliable, and clinically meaningful insights for patient care.
Genomic Test Portfolio to Expand Beyond 500 Assays
Metropolis currently offers more than 220 validated genomic tests and has outlined plans to expand this portfolio to over 500 advanced assays over the next two to three years. The expanded menu will span multiple high-impact disease areas, aligning genomic diagnostics with India-specific disease patterns and evolving clinical pathways.The Centre also brings together molecular pathologists, genomic scientists, researchers, bioinformaticians, and certified genetic counsellors to ensure strong clinical integration and quality-led reporting.
Strategic Focus on Precision Medicine and Research Partnerships
Management highlighted that genomics represents a structural shift in diagnostics, expanding the role of laboratories from disease detection to risk prediction, therapy personalisation, and long-term disease management. The Centre of Genomics is positioned as a platform for continuous test development, AI-enabled analytics, and deeper digital integration.Beyond domestic diagnostics, Metropolis plans to leverage the Centre to support pharmaceutical programs, clinical trials, companion diagnostics, and global research collaborations, strengthening its role in precision-led drug development and international B2B engagements.
With the launch of the Centre of Genomics, Metropolis Healthcare signals a decisive push into advanced, clinically integrated genomics, reinforcing its long-term strategy to scale precision diagnostics and research-led healthcare solutions in India.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.